Articles Vol. 67 No. CĐ4-HN Ký sinh trùng-HN Hóa sinh 2026 21/04/2026

SKIN AUTOFLUORESCENCE AND CUMULATIVE METABOLIC BURDEN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Tang My Ngan1,2, Le Quoc Tuan1,2, Nguyen Thi Bich Dao3,4
1 School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh city
2 Trường Y, Đại học Y Dược thành phố Hồ Chí Minh
3 Tam Duc Heart Hospital
4 Bệnh viện Tim Tâm Đức
DOI: 10.52163/yhc.v67iCD4.4871
21 Views
2 Downloads
Abstract

Objectives: To investigate the association between skin autofluorescence and obesity in patients with type 2 diabetes mellitus, and to evaluate the respective roles of skin autofluorescence and body mass index in relation to glycemic control and renal function.

Methods: A cross-sectional descriptive study was conducted in 149 patients with type 2 diabetes mellitus. Participants were stratified according to body mass index (< 25 kg/m² and ≥ 25 kg/m²). Skin autofluorescence was measured using the AGE Reader mu device. Clinical and biochemical variables included body mass index, HbA1c, and estimated glomerular filtration rate. Poor glycemic control was defined as HbA1c ≥ 7%.

Results: No significant difference in skin autofluorescence levels was observed between body mass index groups (p > 0.05). Lower body mass index was associated with poor glycemic control (HbA1c ≥ 7%) (OR = 0.89; p < 0.05), suggesting a “lean diabetes” phenotype. In contrast, skin autofluorescence has a correlation with age (r = 0.26; p < 0.01) and has an inverse correlation with estimated glomerular filtration rate (r = -0.31; p < 0.01).

Conclusions: Skin autofluorescence was not associated with obesity status but was related to age and renal function in patients with type 2 diabetes, suggesting a potential role of skin autofluorescence as an additional marker reflecting cumulative metabolic burden.

References
[1]
Yamagishi S.I. Role of advanced glycation endproduct (AGE)-receptor for advanced glycation endproduct (RAGE) axis in cardiovascular disease and its therapeutic intervention. Circ J, 2019, 83 (9): 1822-1828. doi: 10.1253/circj.CJ-19-0618. Google Scholar
[2]
Rhee S.Y, Kim Y.S. The role of advanced glycation end products in diabetic vascular complications. Diabetes Metab J, 2018, 42 (3): 188-195. doi: 10.4093/dmj.2017.0105 Google Scholar
[3]
Khalid M, Petroianu G, Adem A. Advanced glycation end products and diabetes mellitus: mechanisms and perspectives. Biomolecules, 2022, 12 (4): 542. doi: 10.3390/biom12040542. Google Scholar
[4]
van Waateringe R.P, Fokkens B.T et al. Skin autofluorescence predicts incident type 2 diabetes, cardiovascular disease and mortality in the general population. Diabetologia, 2019, 62 (2): 269-280. doi: 10.1007/s00125-018-4769-x. Google Scholar
[5]
Monami M, Lamanna C et al. Skin autofluorescence in type 2 diabetes: beyond blood glucose. Diabetes Research and Clinical Practice, 2008, 79 (1): 56-60. Google Scholar
[6]
Lutgers H.L, Graaff R et al. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care, 2006, 29 (12): 2654-9. doi: 10.2337/dc05-2173. Google Scholar
[7]
Sánchez E, Sánchez M et al. Is there a link between obesity indices and skin autofluorescence? A response from the ILERVAS project. Nutrients, 2022, 15 (1): 203. Google Scholar
[8]
Alkhami F, Borderie G et al. Skin autofluorescence of advanced glycation end-products relates to new cardiovascular events in type 2 diabetes: a longitudinal observational study. Diabetes & Metabolism, 2024, 50 (2): 101524. Google Scholar
[9]
Kim J.M, Joung K.H et al. Lean diabetes: 20-year trends in its prevalence and clinical features among Korean adults. BMC Public Health, 2024, 24 (1): 3554. Google Scholar
[10]
Smit A.J, Gerrits E.G. Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2010, 19 (6): 527-33. Google Scholar